Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11475921 | 0.87 | PDPK1 (0.39) | PDPK1ESR1MAPTLMNAPDE5A | |
| SCHEMBL1923963 | 0.84 | HTT (0.42) | PDPK1ESR1MAPTALDH1A1MEN1 | |
| SCHEMBL21611401 | 0.83 | LMNA (0.53) | MAPTALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL21611495 | 0.82 | CYP1A1 (0.44) | MAPTALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL21858763 | 0.82 | TRPA1 (0.50) | MAPTCASP1ALDH1A1MEN1KMT2A | |
| SCHEMBL9160539 | 0.80 | CHEK1 (0.38) | PDPK1ESR1MAPTALDH1A1LMNA | |
| SCHEMBL21542856 | 0.80 | PDPK1 (0.35) | PDPK1ESR1MAPTALDH1A1TSHR | |
| SCHEMBL21611524 | 0.79 | L3MBTL1 (0.46) | MAPTMEN1KMT2ARAB9ALMNA | |
| SCHEMBL21611547 | 0.79 | TRPA1 (0.53) | MAPTALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL28514423 | 0.79 | LMNA (0.39) | ESR1MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250270209-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| EP-4522616-A1 | LRRK2 INHIBITORS | Interline Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119403801-A | LRRK2 inhibitors | 因特来治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-3541804-B1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-22 | — | — | EP | disclosed |
| EP-3541802-B1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-3532474-B1 | 4,5-ANNULATED 1,2,4-TRIAZOLONES | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| CN-114921391-B | 4, 5-cyclic 1,2, 4-triazolones | 拜耳股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-5442060-A | Treating hyperlipemia, atherosclerosis | MITSUBISHI KASEI CORPORATION (JP) | 1995-08-15 | — | — | US | disclosed |
| EP-0591830-A1 | Carboxamide and urea derivatives having ACAT-inhibiting activityM | Mitsubishi Chemical Corporation (JP) | 1994-04-13 | — | — | EP | disclosed |
| EP-0245687-B1 | SUBSTITUTED PYRIMIDINE AMIDES OF OLEIC OR LINOLEIC ACID AS INHIBITORS OF ACYL-COA CHOLESTEROL ACYLTRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1991-02-27 | — | — | EP | disclosed |
| US-4722927-A | ANTICHOLESTEROL AGENTS | WARNER-LAMBERT COMPANY (US) | 1988-02-02 | — | — | US | disclosed |
| EP-0245687-A1 | Substituted pyrimidine amides of oleic or linoleic acid as inhibitors of acyl-coa cholesterol acyltransferase | WARNER-LAMBERT COMPANY (US) | 1987-11-19 | — | — | EP | disclosed |
| US-4657579-A | HERBICIDE | SANDOZ LTD. (CH) | 1987-04-14 | — | — | US | disclosed |
| EP-0039037-B1 | PYRIMIDYLTHIO-UREAS, MEDICINES CONTAINING THEM AND THEIR USE | Beiersdorf Aktiengesellschaft (DE) | 1985-01-16 | — | — | EP | disclosed |
| US-4434167-A | Pyrimidyl thioureas useful for the treatment of hypertension and hyperlipidemia | BEIERSDORF AKTIENGESELLSCHAFT (DE) | 1984-02-28 | — | — | US | disclosed |
| US-4323570-A | HYPOTENSIVE AGENTS AND TREATING GLAUCOMA | BEIERSDORF AKTIENGESELLSCHAFT (DE) | 1982-04-06 | — | — | US | disclosed |
| EP-0039037-A1 | Pyrimidylthio-ureas, medicines containing them and their use | Beiersdorf Aktiengesellschaft (DE) | 1981-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | PDPK1 396/4885ESR1 3463/4885MAPT 4273/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | PDPK1 396/4885ESR1 3463/4885MAPT 4273/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | PDPK1 396/4885ESR1 3463/4885MAPT 4273/4885 |
| US-20250270209-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | PDPK1 73/4885ESR1 4528/4885MAPT 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.